Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

NCT00045201 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

NIH

Sponsor class

Conditions

Adult Solid Neoplasm

Interventions

DRUG: Erlotinib Hydrochloride
DRUG: Irinotecan Hydrochloride

Sponsor

National Cancer Institute (NCI)